Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal - Sorbonne Université Access content directly
Journal Articles Multiple Sclerosis Journal Year : 2021

Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal

Alan J Thompson
William Carroll
Alexis Donnelly
  • Function : Author
Robert J Fox
Anne Helme
  • Function : Author
Robert Hyde
  • Function : Author
Pamela Kanellis
  • Function : Author
Douglas Landsman
  • Function : Author
Ruth Ann Marrie
Julia Morahan
  • Function : Author
Bruno Musch
  • Function : Author
Sarah Rawlings
  • Function : Author
Caroline Sincock
  • Function : Author
Kathryn E Smith
  • Function : Author
Jon Strum
  • Function : Author
Paola Zaratin
  • Function : Author
Timothy Coetzee

Abstract

Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective agents have been mixed. The recent introduction of the term 'active' secondary progressive MS into the therapeutic lexicon has introduced potential confusion to disease description and thereby clinical management. Objective: This paper reviews recent progress, highlights continued knowledge and proposes, on behalf of the International Progressive MS Alliance, a global research strategy for progressive MS. Methods: Literature searches of PubMed between 2015 and May, 2021 were conducted using the search terms "progressive multiple sclerosis", "primary progressive multiple sclerosis", "secondary progressive MS". Proposed strategies were developed through a series of in-person and virtual meetings of the International Progressive MS Alliance Scientific Steering Committee. Results: Sustaining and accelerating progress will require greater understanding of underlying mechanisms, identification of potential therapeutic targets, biomarker discovery and validation, and conduct of clinical trials with improved trial design. Encouraging developments in symptomatic and rehabilitative interventions are starting to address ongoing challenges experienced by people with progressive MS. Conclusion: We need to manage these challenges and realise the opportunities in the context of a global research strategy, which will improve quality of life for people with progressive MS.
Fichier principal
Vignette du fichier
thompson-et-al-2021-charting-a-global-research-strategy-for-progressive-ms-an-international-progressive-ms-alliance.pdf (902.52 Ko) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY NC - Attribution - NonCommercial

Dates and versions

hal-04525034 , version 1 (28-03-2024)

Licence

Attribution - NonCommercial

Identifiers

Cite

Alan J Thompson, William Carroll, Olga Ciccarelli, Giancarlo Comi, Anne Cross, et al.. Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal. Multiple Sclerosis Journal, 2021, 28 (1), pp.16-28. ⟨10.1177/13524585211059766⟩. ⟨hal-04525034⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More